<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7463036\results\search\testTrace\results.xml">
  <result pre="antiviral drug, it is necessary to evaluate oseltamivir in the" exact="treatment" post="of COVID-19. Objective To evaluate the effect of oseltamivir"/>
  <result pre="progression. Conclusions We consider that oseltamivir isnâ€™t suitable for the" exact="treatment" post="of COVID-19. During the outbreak of novel coronavirus, when"/>
  <result pre="with severe COVID-19 on January 29, 2020 underwent a 48h" exact="treatment" post="with lopinavir/ritonavir combined with oseltamivir, which improved the patientâ€™s"/>
  <result pre="oseltamivir for COVID-19, it once again linked oseltamivir to the" exact="treatment" post="of a coronavirus-induced disease. As frontline healthcare workers fighting"/>
  <result pre="healthcare workers fighting against COVID-19, we were interested in the" exact="treatment" post="regimen of this case and found most patients with"/>
  <result pre="primary hospitals. Therefore, if oseltamivir is effective for COVID-19, the" exact="treatment" post="could be family-oriented. If, instead, the treatment effectiveness is"/>
  <result pre="for COVID-19, the treatment could be family-oriented. If, instead, the" exact="treatment" post="effectiveness is not significant, the use of oseltamivir should"/>
  <result pre="oseltamivir against SARS-CoV-2 could have a positive effect on the" exact="treatment" post="of COVID-19. SARS-CoV-2 belongs to the Î²-genus of the"/>
  <result pre="key enzymes of SARS-CoV-2 are important targets for inhibiting SARS-CoV-2" exact="infection" post="[6], [7], [8], [9], [10]. Since the SARS outbreak"/>
  <result pre="before infecting with the SARS-CoV-2 (nCoV-2019BetaCoV/Wuhan/WIV04/2019) at a multiplicity of" exact="infection" post="(MOI) of 0.05 for 2Â h. After that, cell"/>
  <result pre="Study design We retrospectively analyzed 627 patients diagnosed with SARS-CoV-2" exact="infection" post="at the Second Hospital of Wuhan, Wuhan Union Hospital,"/>
  <result pre="The enrollment criteria were: 1. patients were diagnosed with SARS-CoV-2" exact="infection" post="and negative for influenza A and B nucleic acid"/>
  <result pre="start of antiviral therapy to clinical evaluation as a patientsâ€™" exact="treatment" post="period. We defined the patients with relieved symptoms and"/>
  <result pre="symptoms and stable or absorbed lesions in CT during the" exact="treatment" post="period as the remission group, and the patients without"/>
  <result pre="clinical records and progress notes. Besides, pre- and post- antiviral" exact="treatment" post="symptoms were collected and evaluated by front-line medical workers."/>
  <result pre="the previous work [24], [25]. Fig. 5 A showed that" exact="treatment" post="of oseltamivir did not inhibit SARS-CoV-2 replication, with half-inhibitory"/>
  <result pre="Vero E6 cells infected with SARS-CoV-2 were cultured with the" exact="treatment" post="of tested drugs for 24Â h. Viral copy numbers"/>
  <result pre="the dosage of oseltamivir was 300Â mg/day, and our patientsâ€™" exact="treatment" post="dose was still based on the conventional dose of"/>
  <result pre="In summary, we consider that oseltamivir isnâ€™t suitable for the" exact="treatment" post="of COVID-19. During the outbreak of novel coronavirus, when"/>
  <result pre="combined with COVID-19. Therefore, oseltamivir should be combined in the" exact="treatment" post="regimen in a timely manner when influenza occurs. Declaration"/>
 </snippets>
</snippetsTree>
